본문 바로가기

Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q2Scopus Q2
저널
BMJ OPEN5(6) · 2015
피인용
Web of Science 20
JCR IF
JCR 2014 2.271
ISSN
2044-6055

저자

  1. Chin, Sang Ouk제1저자제주대학교, Sch Med, Dept Internal Med, KO
  2. Chung, Choon Hee연세대학교, Wonju Coll Med, Wonju Severance Christian Hosp, KO
  3. Chung, Yoon-Sok아주대학교, Sch Med, Dept Endocrinol & Metab, KO
  4. Kim, Byung-Joon가천대학교, Gil Med Ctr, Dept Endocrinol & Metab, KO
  5. Kim, Hee Young고려대학교, Coll Med, Dept Endocrinol, KO
  6. 김인주부산대학교, 의과대학, 의학과, 내과학교실, KO
  7. Kim, Jung Guk경북대학교, Sch Med, Dept Internal Med, KO
  8. Kim, Min-Seon울산대학교, Coll Med, Asan Med Ctr, KO
  9. Kim, Seong-Yeon서울대학교, Sch Med, Dept Internal Med, KO
  10. Lee, Eun Jig연세대학교, Coll Med, Dept Internal Med, KO
  11. Lee, Ki Young가천대학교, Gil Med Ctr, Dept Endocrinol & Metab, KO
  12. Kim, Sung-Woon교신저자경희대학교, Sch Med, Dept Endocrinol & Metab, KO

초록

Objectives: This study was designed to investigate changes in health-related quality of life (HRQoL) of patients with acromegaly in Korea after medical treatment with octreotide LAR using the validated Korean version of the acromegaly quality of life questionnaire (AcroQoL). Design: A prospective, open-label, single-arm study. Setting: 11 tertiary centres in Korea. Participants: 58 Korean patients (aged 21-72 years) who were newly diagnosed with acromegaly between 2009 and 2012 were prescribed octreotide LAR 20 mg at the time of enrolment. During 24 weeks of observation, AcroQoL survey questionnaires and measurement of growth hormone insulin-like growth factor 1(GH/IGF-I) were performed at baseline, week 12 and week 24. Main outcome measures: We assessed the HRQoL of Korean patients with acromegaly after medical treatment with octreotide LAR using the validated Korean version of the AcroQoL questionnaire. Results: Patients had a mean age of 47.2 years (29 males), and GH and IGF-I significantly decreased during the first 12 weeks (GH: 4.8 vs 1.9 mu g/L, p<0.001; IGF-I: 497 vs 265 mu g/L, p<0.001), but showed insignificant change at week 24 (GH: 2.3 mu g/L; IGF-I: 294 mu g/L). Only AcroQoL scores for the psychological appearance subdomain showed a significant increase during the entire 24 weeks (p<0.05). The change in the psychological appearance subdomain of AcroQoL scores demonstrated a significant but weak negative correlation with change in IGF-I levels (r=-0.282, p=0.039). When patients were divided into two groups according to their disease activity at week 24 (controlled vs uncontrolled), there was no difference in AcroQoL scores, but the psychological appearance subdomain of the two groups appeared to change differently over the entire 24-week period (p=0.047). Conclusions: Medical treatment with octreotide LAR in patients with acromegaly has a limited contribution to HRQoL as assessed by the AcroQoL.

키워드

GROWTH-HORMONELANREOTIDE TREATMENTQUESTIONNAIREMORTALITY

식별자

WoS UID
000363479900016